2133 related articles for article (PubMed ID: 25919163)
1. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Giglio N; Gentile A; Jimenez SG; Jáuregui B; Clark AD; Diosque M; Vizzotti C
Vaccine; 2011 Jul; 29(31):4963-72. PubMed ID: 21621575
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.
Kieninger MP; Caballero EG; Sosa AA; Amarilla CT; Jáuregui B; Janusz CB; Clark AD; Castellanos RM
Vaccine; 2015 May; 33 Suppl 1():A143-53. PubMed ID: 25919155
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.
Mezones-Holguin E; Canelo-Aybar C; Clark AD; Janusz CB; Jaúregui B; Escobedo-Palza S; Hernandez AV; Vega-Porras D; González M; Fiestas F; Toledo W; Michel F; Suárez VJ
Vaccine; 2015 May; 33 Suppl 1():A154-66. PubMed ID: 25919156
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
Kim SY; Lee G; Goldie SJ
BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
Sohn HS; Suh DC; Jang E; Kwon JW
J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
[TBL] [Abstract][Full Text] [Related]
12. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
[TBL] [Abstract][Full Text] [Related]
16. A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.
Vemer P; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):1841-9. PubMed ID: 25424791
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
18. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
19. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran.
Ezoji K; Yaghoubi M; Nojomi M; Mahmoody S; Zahraie SM; Moradi-Lakeh M; Tabatabaei SR; Karimi A
East Mediterr Health J; 2019 Nov; 25(10):686-697. PubMed ID: 31774134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]